Amylyx Pharmaceuticals Inc. (AMLX)
AMLX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1658551/000119312526086645/0001193125-26-086645-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | AMLX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001658551 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$144.7M |
| Operating income | -$153.3M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $226.7M |
| Total assets | $332.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $240.1M cash; operating cash flow -$32.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 128,562,904 (2026-10-26); 109,819,569 a year earlier; 67,517,753 three years earlier. | Cover page 2026-10-26 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-08-20 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $152K, sold $9.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$45.5M | -$33.7M | $240.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$43.4M | -$31.4M | $49.3M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2026 2026-03-31 | Not filed | -$41.3M | -$36.9M | $229.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-12-31 | $0 | -$33.0M | -$27.9M | $226.7M | No debt tags | $0 | 10-K 2026-03-03 |
| Q3 2025 2025-09-30 | $0 | -$34.4M | -$30.4M | $225.2M | No debt tags | -$665K | 10-Q 2025-11-06 |
| Q2 2025 2025-06-30 | $0 | -$41.4M | -$25.2M | $58.1M | No debt tags | -$249K | 10-Q 2025-08-07 |
| Q1 2025 2025-03-31 | $0 | -$35.9M | -$39.8M | $59.8M | No debt tags | -$1.3M | 10-Q 2025-05-08 |
| Q4 2024 2024-12-31 | -$665K | -$37.5M | -$59.0M | $77.4M | No debt tags | $87.4M | 10-K 2026-03-03 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-20 |
| Latest annual report | 10-K | 2026-03-03 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 448 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.7% |
| 1 month | +12.8% |
| 3 months | +34.7% |
| Year to date | +150.7% |
| 1 year | +143.9% |
| From 52-week high | -23.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PBLS | Parabilis Medicines Inc. | $28.45 | +0.07% | $3.5B |
| ABCL | AbCellera Biologics Inc. Common Shares | $11.12 | -3.22% | $3.6B |
| ELVN | Enliven Therapeutics Inc. | $47.62 | -2.42% | $3.5B |
| OGN | Organon & Co. Common Stock | $13.90 | 0.00% | $3.7B |
| IRON | Disc Medicine Inc. | $76.59 | -4.26% | $3.5B |
| ARQT | Arcutis Biotherapeutics Inc. | $27.15 | -3.93% | $3.4B |
| VKTX | Viking Therapeutics Inc. | $26.80 | -8.28% | $3.4B |
| VRDN | Viridian Therapeutics Inc. | $29.80 | -3.47% | $3.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier